Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
boston blog main
boston top stories
drugs
national top stories
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
abeona therapeutics
accent therapeutics
achilles therapeutics
akcea therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceuticals
alopecia areata
amarin
amgen
anylam pharmaceuticals
aridis pharmaceuticals
aristea therapeutics
autoimmune diseases
axitinib
bellus health
biotech
biotech ipos
bolt biotherapeutics
boulder/denver blog main
boulder/denver top stories
bridgebio
bristol-myers squibb
cancer
cannabidiol
What
drug
3
×
sets
3
×
ago
approved
battle
fda
market
patients
rare
advantages
akcea
alnylam
amyloidosis
attr
available
bar
bio
brings
cannabis
data
debilitating
derivative
disease
epilepsy
expect
form
gamble
genetic
gw
gw’s
marijuana
medco’s
medicine
medicines
mover
new
oks
payers
pfizer
pharmaceuticals
Language
unset
Current search:
sets
×
drug
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug